| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| What causes aplastic anaemia? |
|
Leukemia |
Aplastic Anemia |
| Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
|
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Rethinking clinical trial endpoints in myelodysplastic syndromes. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
|
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
|
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
